4EYM

MAPK13 complex with inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.35 Å
  • R-Value Free: 0.269 
  • R-Value Work: 0.203 
  • R-Value Observed: 0.206 

wwPDB Validation 3D Report Full Report



Literature

IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.

Alevy, Y.G.Patel, A.C.Romero, A.G.Patel, D.A.Tucker, J.Roswit, W.T.Miller, C.A.Heier, R.F.Byers, D.E.Brett, T.J.Holtzman, M.J.

(2012) J Clin Invest 122: 4555-4568

  • DOI: 10.1172/JCI64896
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Increased mucus production is a common cause of morbidity and mortality in inflammatory airway diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. However, the precise molecular mechanisms for pathogenic muc ...

    Increased mucus production is a common cause of morbidity and mortality in inflammatory airway diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. However, the precise molecular mechanisms for pathogenic mucus production are largely undetermined. Accordingly, there are no specific and effective anti-mucus therapeutics. Here, we define a signaling pathway from chloride channel calcium-activated 1 (CLCA1) to MAPK13 that is responsible for IL-13-driven mucus production in human airway epithelial cells. The same pathway was also highly activated in the lungs of humans with excess mucus production due to COPD. We further validated the pathway by using structure-based drug design to develop a series of novel MAPK13 inhibitors with nanomolar potency that effectively reduced mucus production in human airway epithelial cells. These results uncover and validate a new pathway for regulating mucus production as well as a corresponding therapeutic approach to mucus overproduction in inflammatory airway diseases.


    Organizational Affiliation

    Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Mitogen-activated protein kinase 13
A
371Homo sapiensMutation(s): 0 
Gene Names: MAPK13PRKM13SAPK4
EC: 2.7.11.24
Find proteins for O15264 (Homo sapiens)
Go to UniProtKB:  O15264
NIH Common Fund Data Resources
PHAROS  O15264
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
0RX
Query on 0RX

Download CCD File 
A
2-(morpholin-4-yl)-N-[4-(pyridin-4-yloxy)phenyl]pyridine-4-carboxamide
C21 H20 N4 O3
DLOAYIHJIDPKJJ-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
0RXIC50:  98747   nM  BindingDB
0RXIC50:  14884   nM  BindingDB
0RXIC50:  98747   nM  PDBBind
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.35 Å
  • R-Value Free: 0.269 
  • R-Value Work: 0.203 
  • R-Value Observed: 0.206 
  • Space Group: P 21 21 21
  • Diffraction Data DOI: 10.15785/SBGRID/89 SBGrid
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 61.11α = 90
b = 69.564β = 90
c = 93.157γ = 90
Software Package:
Software NamePurpose
Blu-Icedata collection
PHENIXmodel building
PHENIXrefinement
HKL-2000data reduction
SCALEPACKdata scaling
PHENIXphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2012-12-19
    Type: Initial release